AmbioPharm: difference between revisions
Diff·revision 10 → 11·03:11, 19 Nov 2025
Difference between revision 10 and revision 11 of AmbioPharm. 1 line changed; the page grew by 201 bytes.
| Revision 10 — 10:15, 12 Nov 2025 AnalyticalAnnie (talk) clarify that a registered business scope is a licensing fact, not a quality assurance 7,763 bytes +946 | Revision 11 — 03:11, 19 Nov 2025 EndotoxinEd (talk) add the catalogue size and label it self-reported 7,964 bytes +201 | ||
|---|---|---|---|
| 12 | | Official site = [https://ambiopharm.net/ Visit AMB at ambiopharm.net] | 12 | | Official site = [https://ambiopharm.net/ Visit AMB at ambiopharm.net] |
| 13 | }} | 13 | }} |
| + | 14 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} | |
| 14 | 15 | ||
| 15 | '''AmbioPharm, Inc.''' (trading as '''AMB'''; ambiopharm.net) is a peptide active-ingredient manufacturer and contract development organisation trading as AmbioPharm from Beijing, China, incorporated in 2003 and supplying research peptides and raw materials with batch documentation.{{r|registry,selfpub}} | 16 | '''AmbioPharm, Inc.''' (trading as '''AMB'''; ambiopharm.net) is a peptide active-ingredient manufacturer and contract development organisation trading as AmbioPharm from Beijing, China, incorporated in 2003 and supplying research peptides and raw materials with batch documentation.{{r|registry,selfpub}} |